Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darovasertib + crizotinib versus investigator's choice in first-line HLA-A*02:01-negative metastatic uveal melanoma
ISRCTN11391038Phase 3Active, not recruiting
- Sponsor
- United BioSource
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of darovasertib and crizotinib in intraocular melanoma (2 arms), sponsored by United BioSource. Primary endpoints: Progression-free survival and Overall survival. Started Jul 2023; status: active, not recruiting.
02
Drugs
darovasertibcrizotinib
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on ISRCTN11391038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11391038.